The risk of acute coronary syndrome in rheumatoid arthritis in relation to tumour necrosis factor inhibitors and the risk in the general population: A national cohort study

Arthritis Research and Therapy

Volumn 16, Issue 3, 2014, Pages

  Ljung, Lotta ^a,b   Askling, Johan ^b   Rantapää Dahlqvist, Solbritt ^a   Jacobsson, Lennart ^c   Klareskog, Lars ^b   Lindblad, Staffan ^b   von Vollenhoven, Ronald ^b   Baecklund, Eva ^d   Cöster, Lars ^e   Forsblad, Helena ^c   Feltelius, Nils ^f   Geborek, Pierre ^g   Kristensen, Lars Erik ^g  

^a UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d UPPSALA UNIVERSITY   (Sweden)

^e LINKÖPING UNIVERSITY   (Sweden)

^f MEDICAL PRODUCTS AGENCY   (Sweden)

^g LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; TUMOR NECROSIS FACTOR; ANTIRHEUMATIC AGENT; BIOLOGICAL PRODUCT; TUMOR NECROSIS FACTOR ALPHA;

ACUTE CORONARY SYNDROME; ADULT; ARTICLE; CARDIOVASCULAR RISK; COHORT ANALYSIS; COMORBIDITY; DISEASE ASSOCIATION; DISEASE DURATION; FEMALE; HUMAN; INCIDENCE; JOINT SURGERY; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; POPULATION; PROPORTIONAL HAZARDS MODEL; RHEUMATOID ARTHRITIS; SOCIOECONOMICS; AGED; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; COMPLICATION; FOLLOW UP; HEALTH SURVEY; KAPLAN MEIER METHOD; OUTCOME ASSESSMENT; PROCEDURES; REGISTER; RISK ASSESSMENT; STATISTICS AND NUMERICAL DATA; SWEDEN;

ACUTE CORONARY SYNDROME; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; BIOLOGICAL PRODUCTS; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); POPULATION SURVEILLANCE; PROPORTIONAL HAZARDS MODELS; REGISTRIES; RISK ASSESSMENT; SWEDEN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84904270084     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar4584     Document Type: Article

References (31)

1. Avina-Zubieta JA, Thomas J, Sadatsafavi M, Lehman AJ, Lacaille D. Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis 2012, 71:1524-1529.
2. Peters MJ, van Halm VP, Voskuyl AE, Smulders YM, Boers M, Lems WF, Visser M, Stehouwer CD, Dekker JM, Nijpels G, Heine R, Dijkmans BA, Nurmohamed MT. Does rheumatoid arthritis equal diabetes mellitus as an independent risk factor for cardiovascular disease? A prospective study. Arthritis Rheum 2009, 61:1571-1579.
3. Solomon DH, Karlson EW, Rimm EB, Cannuscio CC, Mandl LA, Manson JE, Stampfer MJ, Curhan GC. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 2003, 107:1303-1307.
4. Turesson C, Jarenros A, Jacobsson L. Increased incidence of cardiovascular disease in patients with rheumatoid arthritis: results from a community based study. Ann Rheum Dis 2004, 63:952-955.
5. Holmqvist ME, Wedrén S, Jacobsson LT, Klareskog L, Nyberg F, Rantapää-Dahlqvist S, Alfredsson L, Askling J. Rapid increase in myocardial infarction risk following diagnosis of rheumatoid arthritis amongst patients diagnosed between 1995 and 2006. J Intern Med 2010, 268:578-585.
6. Södergren A, Stegmayr B, Lundberg V, Öhman ML, Wållberg-Jonsson S. Increased incidence of and impaired prognosis after acute myocardial infarction among patients with seropositive rheumatoid arthritis. Ann Rheum Dis 2007, 66:263-266.
7. del Rincón ID, Williams K, Stern MP, Freeman GL, Escalante A. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001, 44:2737-2745.
8. Gonzalez A, Maradit Kremers H, Crowson CS, Ballman KV, Roger VL, Jacobsen SJ, O'Fallon WM, Gabriel SE. Do cardiovascular risk factors confer the same risk for cardiovascular outcomes in rheumatoid arthritis patients as in non-rheumatoid arthritis patients?. Ann Rheum Dis 2008, 67:64-69.
9. Innala L, Möller B, Ljung L, Magnusson S, Smedby T, Södergren A, Öhman ML, Rantapää-Dahlqvist S, Wållberg-Jonsson S. Cardiovascular events in early RA are a result of inflammatory burden and traditional risk factors: a five year prospective study. Arthritis Res Ther 2011, 13:R131.
10. Symmons DP, Gabriel SE. Epidemiology of CVD in rheumatic disease, with a focus on RA and SLE. Nat Rev Rheumatol 2011, 7:399-408.
11. Peters MJ, Symmons DP, McCarey D, Dijkmans BA, Nicola P, Kvien TK, McInnes IB, Haentzschel H, Gonzalez-Gay MA, Provan S, Semb A, Sidiropoulos P, Kitas G, Smulders YM, Soubrier M, Szekanecz Z, Sattar N, Nurmohamed MT. EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Ann Rheum Dis 2010, 69:325-331.
12. Carmona L, Descalzo M, Perez-Pampin E, Ruiz-Montesinos D, Erra A, Cobo T, Gómez-Reino JJ, on behalf of the BIOBADASER and EMECAR Groups All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists. Ann Rheum Dis 2007, 66:880-885. on behalf of the BIOBADASER and EMECAR Groups.
13. Dixon WG, Watson KD, Lunt M, Hyrich KL, Silman AJ, Symmons DPM. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor α therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum 2007, 56:2905-2912.
14. Greenberg JD, Kremer JM, Curtis JR, Hochberg MC, Reed G, Tsao P, Farkouh ME, Nasir A, Setoguchi S, Solomon DH, on behalf of the CORRONA Investigators Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Ann Rheum Dis 2011, 70:576-582. on behalf of the CORRONA Investigators.
15. Ljung L, Simard JF, Jacobsson L, Rantapää-Dahlqvist S, Askling J, and the Anti-Rheumatic Therapy in Sweden (ARTIS) Study Group Treatment with tumour necrosis factor inhibitors and the risk of acute coronary syndromes in early rheumatoid arthritis. Arthritis Rheum 2012, 64:42-52. and the Anti-Rheumatic Therapy in Sweden (ARTIS) Study Group.
16. Naranjo A, Sokka T, Descalzo MA, Calvo-Alén J, Hørslev-Petersen K, Luukkainen RK, Combe B, Burmester GR, Devlin J, Ferraccioli G, Morelli A, Hoekstra M, Majdan M, Sadkiewicz S, Belmonte M, Holmqvist AC, Choy E, Tunc R, Dimic A, Bergman M, Toloza S, Pincus T, and the QUEST-RA Group Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. Arthritis Res Ther 2008, 10:R30. and the QUEST-RA Group.
17. Radovits BJ, Popa-Diaconu DA, Popa C, Eijsbouts A, Laan RF, van Riel PL, Fransen J. Disease activity as a risk factor for myocardial infarction in rheumatoid arthritis. Ann Rheum Dis 2009, 68:1271-1276.
18. Solomon DH, Avorn J, Katz JN, Weinblatt ME, Setoguchi S, Levin R, Schneeweiss S. Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis. Arthritis Rheum 2006, 54:3790-3798.
19. Solomon DH, Curtis JR, Saag KG, Lii J, Chen L, Harrold LR, Herrinton LJ, Graham DJ, Kowal MK, Kuriya B, Liu L, Griffin MR, Lewis JD, Rassen JA. Cardiovascular risk in rheumatoid arthritis: comparing TNF-α blockade with nonbiologic DMARDs. Am J Med 2013, 126:730.e9-730.e17.
20. Suissa S, Bernatsky S, Hudson M. Antirheumatic drug use and the risk of acute myocardial infarction. Arthritis Rheum 2006, 55:531-536.
21. Wolfe F, Michaud K. The risk of myocardial infarction and pharmacologic and nonpharmacologic myocardial infarction predictors in rheumatoid arthritis: a cohort and nested case-control analysis. Arthritis Rheum 2008, 58:2612-2621.
22. Askling J, Fored CM, Geborek P, Jacobsson LT, van Vollenhoven R, Feltelius N, Lindblad S, Klareskog L. Swedish registers to examine drug safety and clinical issues in RA. Ann Rheum Dis 2006, 65:707-712.
23. Askling J, van Vollenhoven RF, Granath F, Raaschou P, Fored CM, Baecklund E, Dackhammar C, Feltelius N, Cöster L, Geborek P, Jacobsson LT, Lindblad S, Rantapää-Dahlqvist S, Saxne T, Klareskog L. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor α therapies: Does the risk change with the time since start of treatment?. Arthritis Rheum 2009, 60:3180-3189.
24. Eriksson JK, Neovius M, Ernestam S, Lindblad S, Simard JF, Askling J. Incidence of rheumatoid arthritis in Sweden: a nationwide population-based assessment of incidence, its determinants, and treatment penetration. Arthritis Care Res (Hoboken) 2013, 65:870-878.
25. Neovius M, Simard J, Sundström A, Jacobsson L, Geborek P, Saxne T, Feltelius N, Klareskog L, Askling J, for the ARTIS Study Group Generalisability of clinical registers used for drug safety and comparative effectiveness research: coverage of the Swedish Biologics Register. Ann Rheum Dis 2011, 70:516-519. for the ARTIS Study Group.
26. Neovius M, Simard JF, Askling J, for the ARTIS Study Group Nationwide prevalence of rheumatoid arthritis and penetration of disease-modifying drugs in Sweden. Ann Rheum Dis 2011, 70:624-629. for the ARTIS Study Group.
27. Geborek P, Crnkic M, Petersson IF, Saxne T, for the South Swedish Arthritis Treatment Group Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden. Ann Rheum Dis 2002, 61:793-798. for the South Swedish Arthritis Treatment Group.
28. Jacobsson LT, Turesson C, Gülfe A, Kapetanovic MC, Petersson IF, Saxne T, Geborek P. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol 2005, 32:1213-1218.
29. Jacobsson LT, Rantapää-Dahlqvist S, Nilsson J, Ljung L, Askling J, for the Swedish ARTIS Group Anti-TNF therapy in RA and risk of acute myocardial infarction (AMI), stroke and any cardiovascular (CVD) events up to 7 years after treatment start [abstract]. Arthritis Rheum 2008, 58:S900. for the Swedish ARTIS Group.
30. Wolfe F, Michaud K. The effect of rheumatic disease treatment on the risk of myocardial infarction: increased risk from rofecoxib, valdecoxib and celecoxib; decreased risk from anti-TNF therapy [abstract]. Arthritis Rheum 2007, 56:S535.
31. Barnabe C, Martin BJ, Ghali WA. Systematic review and meta-analysis: anti-tumor necrosis factor α therapy and cardiovascular events in rheumatoid arthritis. Arthritis Care Res (Hoboken) 2011, 63:522-529.